also reported that in HCC patients treated with Atez/Bev, a decrease in AFP level by ≥75% after 6 weeks of treatment effectively distinguished between treatment responders from non-responders, while an increase in AFP level by ≤10% better distinguished between disease control and disease progression (65). The gene discussed is AFP; the disease is hepatocellular carcinoma.